tissue-type plasminogen activator
Accordingly, tissue-type       plasminogen activator (t-PA) is frequently administered to patients with       recurrent infarction presenting more than four days from previous treatment with        streptokinase.
Accordingly,  @SUBJECT$  (t-PA) is frequently  @PREDICAT$  to  @OBJECT$  with       recurrent infarction presenting more than four days from previous treatment with        streptokinase.